SI-BONE Raises FY2021 Sales Guidance $89.00M-90.00M vs 89.4M Est
SI-BONE (NASDAQ:SIBN) raises FY2021 sales outlook from $89.00 million-90.00 million to $89.80 million-90.10 million.
SI-BONE, Inc. Highlights Blue Cross Blue Shield Association Evidence Street Annual Technology Review On iFuse Transiliac Triangular Implants
SI-BONE, Inc., (NASDAQ:SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacro-pelvic anatomy, today announced that Blue Cross Blue Shield Association (BCBSA)
JMP Securities Maintains Market Outperform on SI-BONE, Lowers Price Target to $36
JMP Securities analyst David Turkaly maintains SI-BONE (NASDAQ:SIBN) with a Market Outperform and lowers the price target from $42 to $36.
SI-BONE: Q3 Earnings Insights
SI-BONE (NASDAQ:SIBN) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Return on Capital Employed Insights for SI-BONE
Pulled from Benzinga Pro data SI-BONE (NASDAQ:SIBN) reported Q2 sales of $22.19 million. Earnings fell to a loss of $12.96 million, resulting in a 12.01% decrease from last quarter.
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Return on Capital Employed Insights for SI-BONE
After pulling data from Benzinga Pro it seems like during Q2, SI-BONE (NASDAQ:SIBN) brought in sales totaling $22.19 million. However, earnings decreased 12.01%, resulting in a loss of $12.96 million.